Join the

5th International PatentSight Summit

Panel Discussion:
Patent Analytics at International Patent Offices - Challenges and Expectations

Learn more and register →

Subscribe to News Service

Global Innovation Ranking: Top 100 World's Most Innovative Companies

Webinar - Open Access
 

Watch the recording

Roche up, Pfizer out - The Patent Asset Index™ for Alzheimer’s and Parkinson’s patents

by Benjamin Hann, on Oct 9, 2018 8:28:00 AM

GettyImages-973074712

As of today effective drugs for Alzheimer’s and Parkinson’s diseases are missing. In fact, Pharma giant Pfizer recently announced that they’re ending their research in this field. Which from an innovation analytics point of view does not come as a complete surprise.

The Patent Asset Index™ trend of patents for nervous system disorder drugs reveals that the quality of Pfizer’s patents in this field has been dropping steadily since 2005. Their R&D expenditures simply did not pay off.

In contrast, the patent strength of Roche’s portfolio in the same field is rising steadily.Patent Asset Index for Alzheimer’s and Parkinson’s patents

Topics:"Patent Analysis"Patent ValuationPatent Asset Index

Comments

About PatentSight IP Analytics Blog

Get to know unique Insights into the latest technology topics based on strategic patent analyses.

Subscribe to News

At PatentSight we find exciting news, insights from patent analyses and use cases every day.

If you would like us to keep you informed about new findings, sign up for our news service:

Subscribe to News Service